Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark Launches Tiotropium DPI In Spain

As Company Looks At Several Other European Markets For Tavulus

Executive Summary

India’s Glenmark has announced the launch of Tavulus, its generic version of Boehringer Ingelheim’s Spiriva Handihaler, in Spain. The company is also looking to launch its tiotropium bromide dry powder inhaler in other key European markets. 

You may also be interested in...



Glenmark Expects ‘Strong Year’ With ‘First’ EU Spiriva Rival Imminent

Glenmark said it would continue to deliver new respiratory products in Europe moving forward as the Indian firm lines up what it believes will be the first generic version of Boehringer Ingelheim’s Spiriva Handihaler.

Glenmark inks a deal for Spiriva in Europe

Glenmark is aiming to bolster its burgeoning respiratory presence in Europe by signing an exclusive licensing and marketing agreement with an undisclosed third party for a generic of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) dry-powder inhaler in Western European markets.

Adamis Receives FDA Approval For 505(b)(2) Naloxone

Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022. 

Topics

Related Companies

UsernamePublicRestriction

Register

GB151326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel